Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their careers and family life. Despite these facts, a recent assessment by the Institute for Clinical and Economic Review (ICER) of a new class of migraine treatments – calcitonin gene-related peptide (CGRP) inhibitors – fails to incorporate improvements to patients’ productivity in its price recommendations. ICER’s subjective decision to ignore best practices and exclude productivity benefits shows how its approach skews results to put payer needs over patients.
The burden of disease associated with migraine is significant. Migraine cost employers nearly $13 billion annually due in part to 113 million lost work days. CGRP inhibitors offer new hope to individuals suffering from migraine as the first medicines developed specifically for the prevention of the condition. According to a recent study, CGRP inhibitors could improve patient outcomes and save the economy nearly $400 billion over the next 10 years, including through productivity gains associated with fewer migraine days. The significant impact of productivity on migraine patients makes it an important outcome to consider in any measurement of value of migraine treatments.
In its analysis of CGRP inhibitors, ICER admits that when looking at the value of these treatments from the societal perspective, and when including outcomes such as productivity, the value of the treatments leads to more favorable results. In spite of this, ICER’s final price recommendations exclude the impact of productivity gains and other patient-centered outcomes. This decision not only highlights the subjectivity of ICER’s analysis, it goes against best practices recommended by experts in the field of cost-effectiveness analysis. If ICER’s recommendations were used by payers, it could harm patient access to CGRP inhibitors and prevent them from accessing an important medical advance in the treatment of a costly and debilitating condition.
To learn more about how we can advance a value-driven health care system, visit http://www.phrma.org/value-collaborative.
Lauren Neves
Lauren Neves is Vice President of Policy at PhRMA focusing on the value of cancer medicines, medication adherence, and payment and delivery reform. Prior to joining PhRMA, Lauren earned her law degree and worked as a market access and health policy consultant to health care and pharmaceutical clients.
CMS’ MFN proposals won’t help seniors despite lofty promises
Voters voice concerns on government price controls
Incomplete evaluations undermine patient access to transformational medicine
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Recognizing National Glaucoma Awareness Month
In their own words: Insured Americans support policy reforms that address access and affordability concerns
Navigating the patient experience: Burdens and barriers standing between patients and their care
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Myth vs. Fact: The Senate’s latest price setting proposal
ICYMI: Patients across the country are sharing concerns about government price setting
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
The Patient Perspective: Government price-setting harms patients
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
PhRMA presents research at ISPOR 2022
Spotlighting a growing mental health challenge
Innovative contracts continue to gain traction and improve quality of care
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Getting the 340B program back on track in 2021
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
PhRMA comments to administration on Medicare Part D proposed rule
Keep the Six Protected Classes, protected
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
How much do you know about Medicare Part B?
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Reality check: Value-based contracts are good for patients
New report shows over 500 medicines in development for neurological disorders
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Fact Check Friday: The truth about the cost of 340B to patients
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
PhRMA Foundation recognizes inaugural Challenge Award recipients
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
The journey to better health care requires a holistic view
Medicare Monday: How Part B has evolved over the years
Modernizing FDA regulations to advance a value-driven health care system
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Medicare Monday: A discussion on affordability and access to medicines
17 years (and more) of medical discoveries
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
Biopharmaceutical industry’s success reducing disparities for African Americans
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
How ICER’s assessment of a new class of migraine treatments fails patients
Patients
Value-Driven Health Care
The Value Collaborative
How ICER’s assessment of a new class of migraine treatments fails patients
How ICER’s assessment of a new class of migraine treatments fails patients